Accretion PharmaceuticalsNSE:ACCPL -2.36%30 Return-on-Tangible-Equity is 19.41% as of Mar. 2026, which is 10% above its 10-year median of 17.67. GuruFocus rates NSE:ACCPL with a GF Score™ of 30/100. The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 77.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Accretion Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹98.3 Mil. Accretion Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹506.4 Mil. Therefore, Accretion Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 19.41%.
The historical rank and industry rank for Accretion Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ACCPL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.57 Med: 17.67 Max: 127.04
Current: 19.09
During the past 5 years, Accretion Pharmaceuticals's highest Return-on-Tangible-Equity was 127.04%. The lowest was 2.57%. And the median was 17.67%.
NSE:ACCPL's Return-on-Tangible-Equity is ranked better than 77.58% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:ACCPL: 19.09
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Accretion Pharmaceuticals Return-on-Tangible-Equity Related Terms
Accretion Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Accretion Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.41% mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a Return-on-Tangible-Equity of 19.41% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Accretion Pharmaceuticals and its competitors. This is 10% above median its historical median of 17.67. Over the past decade, Accretion Pharmaceuticals' Return-on-Tangible-Equity has ranged from 2.57 to 127.04. According to the industry distribution chart, Accretion Pharmaceuticals ranks #202 out of 901 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Accretion Pharmaceuticals' Return-on-Tangible-Equity too high?
Accretion Pharmaceuticals' current Return-on-Tangible-Equity of 19.41% is 10% above median its 10-year median of 17.67. Over the past 10 years, this metric has ranged from a low of 2.57 to a high of 127.04. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Accretion Pharmaceuticals' value of 19.41% is 145.7% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #202 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #202 out of 901 companies for Return-on-Tangible-Equity. This places Accretion Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Accretion Pharmaceuticals' value of 19.41% is 145.7% above this benchmark. Historically, Accretion Pharmaceuticals' own Return-on-Tangible-Equity has ranged from 2.57 to 127.04 over the past decade. While the company's 10-year median is 17.67 vs. the industry median of 7.90, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Return-on-Tangible-Equity of 19.41% is 145.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Return-on-Tangible-Equity is 19.41%, which is 10% above median its own 10-year median of 17.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Return-on-Tangible-Equity of 19.41%. The current Return-on-Tangible-Equity is 19.41%, which is 10% above median its 10-year median of 17.67 and 145.7% above the Drug Manufacturers industry median of 7.90. Accretion Pharmaceuticals' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Return-on-Tangible-Equity is 19.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
30GF Score
Get the complete analysis for NSE:ACCPL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 